[A19-83] Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2020
Commission awarded on 27.09.2019 by the Federal Joint Committee (G-BA).
First-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC)
Added benefit neither proven in PD-L1 expression (TPS) < 50% (or with EGFR-mutant or ALK-positive NSCLC after targeted therapies) nor in PD-L1 expression (TPS) ≥ 50%
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.